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Editorial I
Is protection by inhalation agents volatile? Controversies in cardioprotection
The old Latin saying ‘nomen est omen’ suggests that a
name is indicative of, or notorious for, its true but
hidden nature. Likewise, current clinical evidence on
organ protection elicited by ether-derived inhalation
agents (‘anaesthetic preconditioning’) appears volatile or,
to say the least, not fully convincing. In this issue of the
British Journal of Anaesthesia, Piriou and colleagues1
report on sevoflurane preconditioning in patients under-
going on-pump coronary artery bypass graft (CABG)
surgery. Despite some postoperative functional improve-
ment, the primary outcome measure troponin I and some
molecular markers of an effective preconditioning
process in the heart remained unaffected. These rather
disappointing results conflict, at least in part, with pre-
vious more promising clinical reports2 – 6 and call for
clarification.
Motivated by the work of Verdouw and colleagues7 and
Reimer and colleagues,8 Murry and colleagues9 described
for the first time in 1986 the phenomenon termed ‘ischae-
mic preconditioning’ in canine myocardium. Since then,
this potent endogenous protective mechanism has been
confirmed in almost all species, including man.10 11 A few
years later, in 1993, late preconditioning, which reflects a
second delayed window of protection occurring 12–96 h
after initiation of preconditioning, was described.12 13 This
second window of protection is the result of transcriptional
reprogramming, depending on de novo protein synthesis
and is of particular clinical relevance, as it is nearly 30
times longer than the first window, which lasts for only
2–3 h. Today, we know that cardiac preconditioning can
be elicited more safely by pharmacological means than by
brief ischaemic hits. This is of particular relevance for the
already jeopardized diseased heart. Two anaesthesia
research groups independently reported the preconditioning-
mimicking effects of isoflurane in 1997,1415 and isoflurane-
induced delayed protection was first reported in 2003 in a
rabbit model.16 Recently, molecular evidence of delayed
preconditioning after sevoflurane inhalation even at sub-
anaesthetic concentrations (,0.5 MAC) was also reported
in humans.17 Extensive experimental work aimed at
elucidating the complex signalling cascade involved in
anaesthetic-induced preconditioning has so far deciphered
many, but not all, of the underlying mysteries of tissue
protection by ether-derived inhalation agents.10 11 18
Unlike most other preconditioning-inducing agents, which
must be administered directly into the coronary arteries to
be effective without serious side-effects, ether-derived
agents can be safely inhaled and thus act systemically
providing total body protection.
In sharp contrast to the striking overwhelming evidence
of cardioprotection by ether-derived inhalation agents in
the experimental setting, are the results from predomi-
nantly smaller clinical studies. Meta-analyses evaluating
ether-derived inhalation agent protection in patients under-
going CABG surgery recently concluded that there is only
some protection with respect to cardiac function and tropo-
nin release but no evidence of reduced risk of myocardial
infarction or cardiovascular mortality.19 20 Although the
proof of concept for anaesthetic preconditioning was
demonstrated in on-pump CABG patients4 in a placebo-
controlled randomized trial, many questions with respect
to the optimal protective protocol still need to be answered.
Julier and colleagues,4 as opposed to Piriou and col-
leagues,1 used a rather higher sevoflurane concentration
(4 vol.% corresponding to 2 MAC) given for 10 min
with a vaporizer attached to the cardiopulmonary bypass
circuit. As with Piriou’s findings, this study showed
improved cardiac function, as determined by reduced peri-
operative plasma NT-proBNP levels, and for the first time
translocation of protein kinase C (a key molecular mech-
anism in preconditioning) in human myocardium in
response to sevoflurane, but no perioperative reduction in
cardiac necrosis markers. Conversely, other studies have
reported a significant decrease in myocardial necrosis
markers in patients undergoing on-pump CABG2 3 and
more recently aortic valve surgery21 if sevoflurane or des-
flurane was used throughout surgery. Other groups recently
reported similar results.5 6 22
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Data from animal studies investigating volatile anaes-
thetic-induced cardiac protection can help to explain these
varying clinical findings only to a limited extent. First,
laboratory work provides evidence that the early window
of protection elicited by anaesthetic preconditioning exhi-
bits a dose–response with a ceiling effect at 2 MAC,23
and multiple cycles of anaesthetic wash-in/out were found
to be more protective.24 In clinical practice, anaesthetics
are titrated to the degree of surgical stimulation mimicking
multiple cycles of preconditioning. However, surgical
stimulation does not necessarily reflect the extent, the
intensity, and the duration of deleterious ischaemic epi-
sodes, rendering titration of protective levels of volatile
anaesthetics a difficult task. Secondly, since desflurane
enhances the release of catecholamines in the heart,25
which activate supplemental protective signal transduction
pathways, one might expect desflurane to be more protec-
tive than other agents.26 On the other hand, an increased
incidence of atrial fibrillation in patients anaesthetized
with desflurane undergoing on-pump CABG surgery has
been described.2 Thirdly, the length of administration
appears less important in laboratory animals, since
exposures as short as 4 min were found to protect guinea
pig hearts against ischaemia–reperfusion damage.27
However, in the clinical arena, the combined pre- (‘anaes-
thetic preconditioning’) and post-ischaemic (‘anaesthetic
postconditioning’) administration of potent inhalation
agents (‘anaesthetic conditioning’) appears to be most pro-
tective.3 28 29 Lastly, and most important, the preponder-
ance of experimental work evaluating ethers as protective
agents, with the exception of a few studies,30 31 was con-
ducted in healthy young hearts virtually ignoring the pro-
found impact of metabolic (diabetes, hyperlipidaemia),
structural (hypertrophy, remodelling after infarction), and
age-related inhibitory effects on cardioprotection. This is
a clear limitation of most laboratory animal studies. In
the clinical setting, many confounding variables poten-
tially enhance [opioids, nitroglycerin, sildenafil, statins,
cardiopulmonary bypass per se, or blood pressure cuffs
(‘remote’ ischaemic preconditioning)], annihilate, or even
reverse (anti-preconditioning anaesthetics, sulfonylurea
drugs, COX-2 inhibitors, non-steroidal anti-inflammatory
drugs) ether-derived inhalation agent cardioprotection.11 In
view of this complex interplay, detailed reporting on poss-
ible confounding factors is essential in clinical studies.
Perioperatively used opioids can effectively induce early
and delayed preconditioning via m-, d-, and k-opioid
receptors, as shown in the study by Li and colleagues32 in
this issue of the British Journal of Anaesthesia and other
previous reports.33 So far, beta-blockers have not been
found to inhibit anaesthetic protection, at least in the clini-
cal setting.1 – 6 21 22 29 NO-releasing beta-blockers such as
nipradilol or nebivolol are capable of eliciting precondi-
tioning.11 Moreover, previous studies did not sufficiently
evaluate the impact of various surgical techniques, the
number of surgeons, and patient-specific genetic profile on
anaesthetic organ protection. Single nucleotide polymorph-
isms (‘genetic background’) related to G-protein coupled
receptors or downstream signalling targets may prove to
be relevant for inhalation agent heart protection. Also,
future clinical studies in the field should separate intrinsic
(genetic) from extrinsic (environmental) factors modu-
lating cardioprotection. The significance of transcriptional
background activity in cardioprotection is supported by
recent findings showing that anaesthetic-induced and con-
stitutive gene regulatory control of myocardial substrate
metabolism predicts postoperative cardiac function in
patients undergoing CABG surgery.29
Piriou’s study,1 although not placebo-controlled, is
clearly an important contribution to our current knowledge
of anaesthetic protection in the heart. Such studies are
necessary to identify the right target patients, who clearly
benefit most from the treatment, and to refine the protec-
tive anaesthetic protocols. Piriou’s study also highlights
the need to objectify for ‘cardioprotection’ at the
functional and biomarker level, such as pulmonary artery
catheter measurements, echocardiography, and cardiac
enzymes and hormones, as cardiac necrosis may be pre-
vented by optimal cardioplegia, but postoperative cardiac
dysfunction (stunning) may still occur and be receptive
to protection.1 4 22 Conversely, determination of tissue
enzyme activity, consistent with an effective precondition-
ing process at the molecular level, is difficult in human
specimens because of limitations, such as significant time
delay during collection and mechanical manipulation, and
thus may be less reliable. Most importantly, the assess-
ment of ‘outcome’ in future preconditioning studies
should not be confined to the immediate perioperative
period but should include long-term cardiovascular evalu-
ation.34 Data from patients with acute coronary syndrome
and myocardial infarction suggest that pre-infarct angina, a
correlate of ischaemic preconditioning, can markedly
improve long-term survival. Similarly, pharmacological
preconditioning, which profoundly diminishes the perio-
perative inflammatory response, including high-sensitivity
C-reactive protein and pregnancy-associated plasma
protein A release,29 may prevent coronary plaque ruptures
and slow the progression of coronary occlusion (statin-like
effects), thereby reducing the incidence of mid- and long-
term cardiovascular complications.34
In this issue of the British Journal of Anaesthesia,
Walsh and colleagues35 review the current literature on
remote ischaemic preconditioning, a fascinating alternative
strategy to provide whole body protection. The intriguing
concept of solvent transferable humoral triggers protecting
at a distance was first observed in a rat heart model where
a close correlation between area at risk and infarct size
was exclusively observed in preconditioned-protected
but not unprotected hearts, implying the presence of
a protective agent acting at remote, that is intra- and
inter-organ sites. Remote ischaemic and anaesthetic
preconditioning share many signalling steps. However,
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important disparities remain. First, interrupting blood flow
by cross-clamping or blood pressure cuffs harbours the
risk of thrombosis, plaque rupture, and embolization.
Secondly, the right dose of ischaemia as the precondition-
ing trigger is less well controlled than the monitored
application of volatile anaesthetics. Thirdly, experimental
and clinical studies provide evidence that aged and dis-
eased hearts may become resistant to ischaemic but much
less to pharmacological preconditioning.36 Finally, it
remains elusive whether (remote) ischaemic and pharma-
cological preconditioning act synergistically or antagonize
each other. Yet, nicorandil, a preconditioning-mimicking
drug, was previously reported to inhibit ischaemic
preconditioning.11
In summary, many experimental studies support the
concept that ether-derived inhalation agents provide strong
protection against ischaemia–reperfusion injury in the
heart and other vital organs. Under clinical conditions,
with many confounding variables, inhalation protection
may appear ‘volatile’. However, this protection is safe and
devoid of the thread of further destabilizing inflamed
plaques, as potentially may occur in ischaemic precondi-
tioning. A recent landmark article discussing the need for
translation of basic science into clinical practice proposes
inhalation agents as readily available model drugs to suc-
cessfully reproduce cardioprotection in clinical practice.37
The work by Piriou and colleagues is a further step into
this direction. Clearly, future experimental studies and
larger-scale clinical trials are needed to discover all the
cytoprotective secrets of Morton’s ether sponge!
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Editorial II
Confidential enquiries into anaesthetic deaths
The purpose of confidential enquiries into anaesthetic
deaths has been to identify the cause of death and find
areas of substandard care that might be amenable to correc-
tion. The enquiries with which anaesthetists in the UK have
been most familiar with are the Confidential Enquiries into
Maternal Deaths (CEMD), the Confidential Enquiries into
Stillbirths and Deaths in Infancy (CESDI), and the National
Confidential Enquiries into Perioperative Deaths
(NCEPOD, now an acronym for National Confidential
Enquiries into Perioperative Outcomes and Death). There is
also a Confidential Enquiry into suicides and homicides.
The organizations of CEMD and CESDI were taken over in
2003 by the Confidential Enquiries into Maternal and Child
Health (CEMACH) which additionally has the role of
looking at health issues related to these groups.
Repeated audits of deaths have a monitoring role as to
whether the number of deaths are increasing or decreasing
and whether new or different causes of death assume prom-
inence with a need to address the cause.
CEMD has been producing triennial reports since 1952
classifying deaths directly due to pregnancy according to
cause, such as haemorrhage, hypertensive diseases, throm-
boembolism, anaesthesia, etc. Achieving this level of
information requires a detailed report on each death and
interpretation by a series of assessors. The report celebrat-
ing 50 yr of these enquiries gives a potted history of
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